Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
expert roundtables Overview Molecular and genomic tests have the potential to add key prognostic data to the assessment of earlier-stage prostate cancer. Ongoing trials seek to validate the use of genomic risk stratification as a means of selecting patients for tailored therapeutic interventions. Q: How is the approach to high-risk, locally advanced disease evolving to incorporate genomics and molecular testing? Tanya B.
FREE with registration! Log in or register to access the full article. References 1. DeWeese, TL ∙ Manzanera, A ∙ Sylvester, J ∙ et al., the PrTK03 study team Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial Lancet Oncol. 2026; 27:673-685 2. Singh, S ∙ Moore, CM ∙ Punwani, S ∙ et al.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
